Artificial intelligence in genitourinary pathology: A translational readiness map

Background and objectives

Artificial intelligence (AI) translation in genitourinary (GU) pathology has progressed unevenly across organs and tasks. This review addresses a central clinical question: which GU pathology AI applications are deployment-ready, which require further validation, and what frameworks can guide safe implementation? We synthesize evidence across GU organs and introduce pragmatic translation frameworks to guide deployment and prioritize translational research.

Methods

Narrative review integrating foundational literature with targeted 2023–2025 publications, emphasizing regulatory milestones, external validation, and prospective studies. Literature was identified through PubMed, Embase, and conference proceedings using structured search terms for AI, digital pathology, and GU organ-specific queries. For each organ/task, we mapped evidence strength, regulatory maturity, generalizability, workflow integration, safety, and feasibility to a Translational Readiness Index (TRI) rubric (0–30 scale).

Results

Prostate biopsy AI demonstrates the strongest maturity (TRI 26/30), supported by U.S. Food and Drug Administration-cleared systems, multi-site validation, and prospective implementations showing efficiency gains and reduced ancillary testing. Bladder cytology shows moderate readiness (TRI 19/30), with commercial offerings supporting pilotable prescreening workflows aligned with the Paris System when paired with uncertainty-aware deferral. Bladder histology, renal neoplasia, and low-prevalence domains (testis, penis) remain emerging (TRI 6–15/30), constrained by label variability, rare subtype underrepresentation, and limited external validation.

Conclusions

The center of gravity in GU pathology AI is moving from isolated task assistance to clinical assurance. Translation is most reliable when case volumes are high, labels are stable, datasets are multi-institutional, and outputs are embedded into workflows with clear intended use, quality gates, and continuous performance monitoring.

Prostate pathology remains the most mature example of clinical integration, with multiple commercial solutions supported by regulatory clearances, multi-site validation, and prospective reader-in-the-loop implementations demonstrating meaningful efficiency gains and increased standardization of quantification and grading-adjacent tasks. The most defensible near-term value is a structured human-AI partnership: region-level localization, consistent quantitative summaries, and reproducibility improvements under pathologist control, backed by auditable QA.

Bladder cytology is the most pilotable non-prostate GU domain for prescreening workflows when paired with explicit adequacy thresholds, uncertainty-aware deferral, and traceable evidence artifacts aligned with Paris System categories. By contrast, bladder histology and renal neoplasia remain emerging domains where interobserver variability, artifact susceptibility, and under-representation of rare variants elevate the risk of silent failure unless systems incorporate robust abstention behavior, external validation across heterogeneous sites, and continuous drift surveillance.

For low-prevalence domains (testis, penis), the limiting factor is less algorithmic promise than data reality. Translation will require consortium-level aggregation, carefully defined endpoints, and transfer-learning strategies evaluated with enriched external test sets and subtype-aware reporting. Foundation and VLMs may reduce labeling burden and improve adaptation in low-data settings, but they do not replace the translational requirements of evidence grounding, uncertainty calibration, auditability, and governance.

The TRI rubric, SURE-Path minimum safety bundle, and the VALIDATED-ORCHESTRATE implementation pathway convert a rapidly expanding literature into operational decisions for clinical and translational pathology audiences. Used together, these frameworks help laboratories define intended use, validate locally in shadow mode, deploy with measurable safeguards, and monitor performance over time using workflow and quality outcomes. Ultimately, the institutions best positioned to benefit are those that adopt available tools with disciplined validation, realistic scope, and rigorous governance, treating AI as a monitored clinical instrument.

Full text

https://www.xiahepublishing.com/2771-165X/JCTP-2025-00056

The study was recently published in the Journal of Clinical and Translational Pathology.

Journal of Clinical and Translational Pathology (JCTP) is the official scientific journal of the Chinese American Pathologists Association (CAPA). It publishes high quality peer-reviewed original research, reviews, perspectives, commentaries, and letters that are pertinent to clinical and translational pathology, including but not limited to anatomic pathology and clinical pathology. Basic scientific research on pathogenesis of diseases as well as application of pathology-related diagnostic techniques or methodologies also fit the scope of the JCTP.

Follow us on X: @xiahepublishing

Follow us on LinkedIn:  Xia & He Publishing Inc.